Peter A. Thompson

Insider Reports History

Entity
Individual
Location
C/O Anthera Pharmaceuticals, Inc., 25801 Industrial Boulevard, Suite B, Hayward, CA
Signature
/s/ Peter A. Thompson
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Peter A. Thompson:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Corvus Pharmaceuticals, Inc. Director, 10%+ Owner Common Stock, $0.0001 par value 6.94M $12M $1.73 Jun 13, 2024 Indirect
Edgewise Therapeutics, Inc. Director, 10%+ Owner Common Stock 444K $8.93M $20.13 Apr 3, 2025 Indirect
Corvus Pharmaceuticals, Inc. Director, 10%+ Owner Pre-Funded Warrants (right to buy) 1.44M $2.5M $1.73 May 6, 2024 Indirect
Janux Therapeutics, Inc. Director Common Stock 231K $1.36M $5.87 Dec 29, 2021 Indirect
ALPINE IMMUNE SCIENCES, INC. Director Common Stock 0 $0 $6.33 May 18, 2024 Indirect
ARS Pharmaceuticals, Inc. Director Common Stock 0 $0 $13.00 Aug 26, 2024 Indirect
Sionna Therapeutics, Inc. Director Common Stock 3.7M Feb 10, 2025 By OrbiMed Private Investments VIII, LP
Corvus Pharmaceuticals, Inc. Director, 10%+ Owner Common Warrants (right to buy) 1.4M May 6, 2024 Indirect
ARS Pharmaceuticals, Inc. Director Stock Option (right to buy) 40K Jun 20, 2024 Direct
Edgewise Therapeutics, Inc. Director, 10%+ Owner Stock Options (Right to buy) 20.6K Jun 10, 2024 Direct
PMV Pharmaceuticals, Inc. Director, 10%+ Owner Stock option (right to buy) 16.3K Jun 2, 2022 Direct
Corvus Pharmaceuticals, Inc. Director, 10%+ Owner Stock Option (Right to Buy) 15K Jun 13, 2024 Direct
Janux Therapeutics, Inc. Director Stock Option (right to buy) 12.5K Jun 14, 2022 Direct
Decibel Therapeutics, Inc. Director, 10%+ Owner Stock Option (right to buy) 10K Jun 17, 2022 Direct
ALPINE IMMUNE SCIENCES, INC. Director Stock Option (Right to buy) 0 May 20, 2024 Direct
ALPINE IMMUNE SCIENCES, INC. Director Warrant (Right to Buy) 0 Jan 11, 2024 Indirect
Janux Therapeutics, Inc. Director Series A Convertible Preferred Stock 0 Jun 15, 2021 Indirect
Janux Therapeutics, Inc. Director Series B Convertible Preferred Stock 0 Jun 15, 2021 Indirect
Sionna Therapeutics, Inc. Director Series B convertible preferred stock 0 Feb 10, 2025 By OrbiMed Private Investments VIII, LP
Sionna Therapeutics, Inc. Director Series C convertible preferred stock 0 Feb 10, 2025 By OrbiMed Private Investments VIII, LP

Insider Reports Filed by Peter A. Thompson

Symbol Company Period Transactions Value $ Form Type Date Filed Role
EWTX Edgewise Therapeutics, Inc. Apr 3, 2025 2 $10M 4 Apr 4, 2025 Director, 10%+ Owner
SION Sionna Therapeutics, Inc. Feb 10, 2025 4 $9.9M 4 Feb 10, 2025 Director
SION Sionna Therapeutics, Inc. Feb 6, 2025 0 $0 3 Feb 6, 2025 Director
SPRY ARS Pharmaceuticals, Inc. Aug 26, 2024 1 -$1.09M 4 Aug 28, 2024 Director
SPRY ARS Pharmaceuticals, Inc. Aug 21, 2024 4 -$11.5M 4 Aug 23, 2024 Director
SPRY ARS Pharmaceuticals, Inc. Jun 20, 2024 1 $0 4 Jun 24, 2024 Director
CRVS Corvus Pharmaceuticals, Inc. Jun 13, 2024 1 $0 4 Jun 17, 2024 Director, 10%+ Owner
EWTX Edgewise Therapeutics, Inc. Jun 10, 2024 1 $0 4 Jun 12, 2024 Director, 10%+ Owner
ALPN ALPINE IMMUNE SCIENCES, INC. May 18, 2024 9 $0 4 May 20, 2024 Director
CRVS Corvus Pharmaceuticals, Inc. May 6, 2024 2 $2.5M 4 May 8, 2024 Director, 10%+ Owner
EWTX Edgewise Therapeutics, Inc. Jan 23, 2024 1 $5M 4 Jan 25, 2024 Director, 10%+ Owner
ALPN ALPINE IMMUNE SCIENCES, INC. Jan 11, 2024 2 $1.85M 4 Jan 16, 2024 Director
ALPN ALPINE IMMUNE SCIENCES, INC. Jan 2, 2024 1 $0 4 Jan 4, 2024 Director
ALPN ALPINE IMMUNE SCIENCES, INC. Dec 27, 2023 6 -$28.7M 4 Dec 29, 2023 Director
CRVS Corvus Pharmaceuticals, Inc. Dec 6, 2023 1 $0 4 Dec 8, 2023 Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Aug 29, 2023 1 $3.1M 4 Aug 31, 2023 Director
SPRY ARS Pharmaceuticals, Inc. Jun 27, 2023 1 $0 4 Jun 28, 2023 Director, 10%+ Owner
CRVS Corvus Pharmaceuticals, Inc. Jun 15, 2023 1 $0 4 Jun 20, 2023 Director, 10%+ Owner
EWTX Edgewise Therapeutics, Inc. Jun 12, 2023 1 $0 4 Jun 14, 2023 Director, 10%+ Owner
ALPN ALPINE IMMUNE SCIENCES, INC. Jan 3, 2023 1 $0 4 Jan 5, 2023 Director
EWTX Edgewise Therapeutics, Inc. Sep 16, 2022 1 $5M 4 Sep 16, 2022 Director, 10%+ Owner
CRVS Corvus Pharmaceuticals, Inc. Aug 11, 2022 1 $0 4 Aug 15, 2022 Director, 10%+ Owner
EWTX Edgewise Therapeutics, Inc. Jun 24, 2022 1 $0 4 Jun 28, 2022 Director, 10%+ Owner
DBTX Decibel Therapeutics, Inc. Jun 17, 2022 1 $0 4 Jun 21, 2022 Director, 10%+ Owner
CRVS Corvus Pharmaceuticals, Inc. Jun 15, 2022 1 $0 4 Jun 17, 2022 Director, 10%+ Owner
JANX Janux Therapeutics, Inc. Jun 14, 2022 1 $0 4 Jun 16, 2022 Director
SPRY Silverback Therapeutics, Inc. Jun 10, 2022 1 $0 4 Jun 13, 2022 Director, 10%+ Owner
EWTX Edgewise Therapeutics, Inc. May 18, 2022 1 $995K 4 May 20, 2022 Director, 10%+ Owner
ALPN ALPINE IMMUNE SCIENCES, INC. Jan 3, 2022 1 $0 4 Jan 4, 2022 Director, 10%+ Owner
JANX Janux Therapeutics, Inc. Dec 29, 2021 2 -$820K 4 Dec 30, 2021 Director
JANX Janux Therapeutics, Inc. Dec 21, 2021 2 -$2.27M 4 Dec 23, 2021 Director
JANX Janux Therapeutics, Inc. Dec 16, 2021 2 -$7.5M 4 Dec 17, 2021 Director
CRVS Corvus Pharmaceuticals, Inc. Sep 20, 2021 1 -$6.76M 4 Sep 22, 2021 Director, 10%+ Owner
ALPN ALPINE IMMUNE SCIENCES, INC. Sep 17, 2021 2 $9.5M 4 Sep 21, 2021 Director, 10%+ Owner
CRVS Corvus Pharmaceuticals, Inc. Sep 9, 2021 1 $0 4 Sep 13, 2021 Director, 10%+ Owner
JANX Janux Therapeutics, Inc. Jun 15, 2021 8 $12M 4 Jun 16, 2021 Director
CRVS Corvus Pharmaceuticals, Inc. Jun 15, 2021 1 $0 4 Jun 16, 2021 Director, 10%+ Owner
JANX Janux Therapeutics, Inc. Jun 10, 2021 1 $0 4 Jun 14, 2021 Director, 10%+ Owner
JANX Janux Therapeutics, Inc. Jun 10, 2021 0 $0 3 Jun 10, 2021 Director
SPRY Silverback Therapeutics, Inc. Jun 4, 2021 1 $0 4 Sep 21, 2021 Director, 10%+ Owner
PMVP PMV Pharmaceuticals, Inc. Jun 2, 2021 1 $0 4 Jun 9, 2021 Director, 10%+ Owner